

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

溫

BUSINESS AND FINANCIAL REVIEW

As of the date of this announcement, the Company and its subsidiaries have continued their normal business operations.

PUBLIC FLOAT AND OWNERSHIP COMPOSITION OF THE H SHARES OF THE COMPANY

As at the date of this announcement, the public float status and the ownership composition of the H Shares of the Company are detailed in the table below:

Holder	Number of H Shares	Percentage
Dr. WANG Hongyue (younger sister of Ms. WANG Lianying)	52,760,000	74.94%
OrbiMed Advisors LLC	17,639,100	25.06%
OrbiMed Capital LLC	667,400	0.5%
OrbiMed Partners Master Fund Limited	149,300	0.21%
OrbiMed Partners, L.P.	209,100	0.30%
UBS Group AG	309,000	0.44%
ZOU Haili	1,454,000	2.07%
Kangning Success Holding Limited	2,150,900	3.06%
Other public	1,279,900	1.82%
Total	70,997,100	100%

The Company will continue to monitor the issue of insufficient public float and will make monthly announcements in accordance with the Listing Rules to keep Shareholders and the market informed of the progress made in restoring the public float. The Company will not undertake any actions that may further reduce its percentage of public float.

本公司將繼續監察公眾浮現不足的問題，並會按照上市規則作出每月公告，以通知股東及市場有關恢復公眾浮現的進展。本公司將不會採取任何可能進一步減少其公眾浮現百分比的行動。

By order of the Board

 **郭 榮 華**
Chairman

Zhejiang, the PRC
 March 2, 2026

As at the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive directors are Mr. Q N Hao and Mr. L Changhao; and the independent non-executive directors are Ms. ZHONG Wentang, Ms. N Ling and Mr. CHAN Sai Keung Hugo.